Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. May 14, 2011; 17(18): 2288-2301
Published online May 14, 2011. doi: 10.3748/wjg.v17.i18.2288
Published online May 14, 2011. doi: 10.3748/wjg.v17.i18.2288
Doses | Cells | Targets |
From 5 to 50 μmol/L | Hepatocytes | Inhibition of NF-κB-mediated signaling |
Mean: 15 μmol/L | Endothelial cells | Suppression of IκBα phosphorylation |
Platelets | Inhibition of protein kinase kinase | |
Cancer cells | Inhibition of c-jun N-terminal kinase | |
Phagocytes | Inhibition of leukotriene formation | |
Stellate cells | Inhibition of release of cytochrome c | |
HepG2 | Inhibition of ERK, MEK, and Raf phosphorylation; inhibition of release of caspase 9 and 3, IL-8, and of PDGF- and TGF-β-mediated signaling; decrease of MMP2; increase of TIMP2; inhibition of HCV replication |
- Citation: Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011; 17(18): 2288-2301
- URL: https://www.wjgnet.com/1007-9327/full/v17/i18/2288.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i18.2288